###begin article-title 0
###xml 87 93 <span type="species:ncbi:10090">Murine</span>
Differential Role for CD80 and CD86 in the Regulation of the Innate Immune Response in Murine Polymicrobial Sepsis
###end article-title 0
###begin p 1
Conceived and designed the experiments: MW JAG. Performed the experiments: AN HK BN AK YH SH MRK WNR JAG. Analyzed the data: AN JAG. Contributed reagents/materials/analysis tools: MW JAG. Wrote the paper: AN JAG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
Inflammation in the early stages of sepsis is governed by the innate immune response. Costimulatory molecules are a receptor/ligand class of molecules capable of regulation of inflammation in innate immunity via macrophage/neutrophil contact. We recently described that CD80/86 ligation is required for maximal macrophage activation and CD80/86-/- mice display reduced mortality and inflammatory cytokine production after cecal ligation and puncture (CLP). However, these data also demonstrate differential regulation of CD80 and CD86 expression in sepsis, suggesting a divergent role for these receptors. Therefore, the goal of this study was to determine the individual contribution of CD80/86 family members in regulating inflammation in sepsis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 175 178 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 317 309 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 565 571 <span type="species:ncbi:9606">humans</span>
###xml 743 748 <span type="species:ncbi:10090">mouse</span>
CD80-/- mice had improved survival after CLP when compared to WT or CD86-/- mice. This was associated with preferential attenuation of inflammatory cytokine production in CD80-/- mice. Results were confirmed with pharmacologic blockade, with anti-CD80 mAb rescuing mice when administered before or after CLP. In vitro, activation of macrophages with neutrophil lipid rafts caused selective disassociation of IRAK-M, a negative regulator of NF-kappaB signaling from CD80; providing a mechanism for preferential regulation of cytokine production by CD80. Finally, in humans, upregulation of CD80 and loss of constitutive CD86 expression on monocytes was associated with higher severity of illness and inflammation confirming the findings in our mouse model.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
In conclusion, our data describe a differential role for CD80 and CD86 in regulation of inflammation in the innate immune response to sepsis. Future therapeutic strategies for blockade of the CD80/86 system in sepsis should focus on direct inhibition of CD80.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 193 196 193 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Angus1">[1]</xref>
###xml 198 201 198 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hotchkiss1">[2]</xref>
###xml 268 270 268 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 302 305 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Martin1">[3]</xref>
###xml 478 481 478 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Angus1">[1]</xref>
###xml 483 486 483 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hotchkiss1">[2]</xref>
###xml 116 122 <span type="species:ncbi:9606">people</span>
Sepsis, the systemic inflammatory response to infection (SIRS), is a devastating condition affecting nearly 750,000 people/year and resulting in over $17billion/year in health care expenditure [1], [2]. Currently, sepsis is the leading cause of death in the ICU and 10th leading cause of death overall [3]. However, in spite of maximal supportive care and appropriate antimicrobial therapy, mortality remains in excess of 25% underscoring the need for better adjuvant therapies [1], [2].
###end p 9
###begin p 10
###xml 442 445 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Abraham1">[4]</xref>
###xml 447 450 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Opal1">[5]</xref>
###xml 569 572 562 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Saha1">[6]</xref>
###xml 824 827 810 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Remick1">[7]</xref>
###xml 829 832 815 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Remick2">[8]</xref>
###xml 834 837 820 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Remick3">[9]</xref>
###xml 673 679 <span type="species:ncbi:9606">humans</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
The innate immune response forms the corner stone of regulation of inflammation and pathogen control in sepsis. This is characterized by an initial burst of pro-inflammatory cytokines, such as IL-6, TNF-alpha and IL-1beta, which in controlled settings, can recapitulate many of the clinical findings of sepsis. However, numerous trials have shown that neutralization of any of these cytokines individually has little to no impact on survival [4], [5]. One potential reason for their failure is the redundant and overlapping nature of many of these individual cytokines [6]. For example, while neutralization of ether TNF-alpha or IL-1beta has little effect on mortality in humans or in mice subjected to lethal polymicrobial sepsis via Cecal Ligation and Puncture (CLP), combined neutralization does improve survival in CLP [7], [8], [9]. As a result, many investigators have begun to target receptors/mediators capable of simultaneously regulating numerous pro-inflammatory cytokines.
###end p 10
###begin p 11
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Gold1">[10]</xref>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-MalmborgHager1">[11]</xref>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Kopf1">[12]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Gold2">[13]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Sharpe1">[15]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Grohmann1">[16]</xref>
###xml 637 640 637 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 641 646 <span type="species:ncbi:10090">mouse</span>
Costimulatory molecules are one class of receptors which have recently been implicated as fulfilling this role in the innate immune response [10], [11], [12], [13]. CD80 and CD86 represent one class of costimulatory receptors. They are stimulated via CD28 while CTLA4 serves as both a stoichiometric inhibitor of CD28-CD80/86 engagement as well as serving to directly induce immunosuppressive signals within dendritic cells [14], [15], [16]. Given the high degree of homology and functional overlap between CD80 and CD86, studies investigating their function have sought to either inhibit their common ligand (CD28) or to use a CD80/CD86-/- mouse.
###end p 11
###begin p 12
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 491 495 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 497 504 493 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 615 619 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
While a large body of evidence points to a critical role for the CD28-CD80/86 system in regulating inflammation in autoimmune disease and graft vs. host disease in the adaptive immune response, our group and others have now described a similar role in the innate immune response. Specifically, neutrophils expressing CD28 activate macrophages in a contact dependent manner via engagement of CD80/86 [17]. In turn, CD80/86 signal via NF-kappaB to induce numerous cytokines, most notable IL-6 [14]. In vivo, deletion or blockade of CD80/86 improves survival and attenuates pro-inflammatory cytokine production in CLP [18].
###end p 12
###begin p 13
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 383 390 383 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Okano1">[19]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hosiawa1">[20]</xref>
###xml 799 805 <span type="species:ncbi:10090">murine</span>
###xml 884 890 <span type="species:ncbi:9606">humans</span>
However, these studies also demonstrated that monocyte expression of CD80 and CD86 were differentially regulated in sepsis [18]. Specifically, sepsis was associated with an increase in CD80 expression, while there appeared to be a downregulation of constitutive CD86 expression. Further, recent studies suggest CD80 and CD86 have differential regulation in the inflammatory response in vivo in diseases regulated by the adaptive immune response, including allergic rhinitis and graft rejection [19], [20]. Combined, these data imply a possible differential role for CD80 and CD86 in regulating mortality and inflammation in the innate immune response as well. Consequently, the goals of this study were to determine the individual contribution of CD28, CD80 and CD86 to the inflammatory response in murine sepsis, and to better correlate expression of these molecules with outcome in humans with sepsis and septic shock.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Ethics Statement
###end title 15
###begin p 16
###xml 157 162 <span type="species:ncbi:9606">human</span>
All animal studies were approved by the New York University and Oregon Health and Sciences University Institutional Animal Care & Use Committee (IACUC). For human studies, the protocol was approved by the Oregon Health and Sciences University Institution Review Board and written consent was obtained from all subjects or their designated representative.
###end p 16
###begin title 17
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 17
###begin p 18
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 237 264 237 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cecal Ligation and Puncture</bold>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Gold1">[10]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-MalmborgHager1">[11]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Kopf1">[12]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Gold2">[13]</xref>
###xml 638 642 638 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Gold1">[10]</xref>
###xml 851 853 839 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ip</italic>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">Mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">Mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 893 896 <span type="species:ncbi:10116">Rat</span>
6-8 week old female C57BL/6 (WT), CD28-/-, CD80-/- and CD86-/- mice were purchased from Jackson Labs. All mice were on a C57BL/6 background. Mice were allowed to acclimatize for 1 week prior to use. All mice were housed in SPF facility. Cecal Ligation and Puncture. CLP was performed as previously described [10], [11], [12], [13]. Briefly, mice were anesthetized with 2.5% isoflourane and underwent CLP with a 19 gauge needle. Mice received 1 cc 0.9% saline subcutaneously for resuscitation. At specified times, the mice were used to collect plasma, bronchoalveolar lavage (BAL) and peritoneal lavage (PL) (3 cc) as previously described [10]. For survival experiments, mice were monitored for a total of 14 days. For antibody inhibition, 250 microg of alpha-CD80 (16-10A1; hybridoma from ATCC) or alpha-CD86 (GL-1, hybridoma from ATCC) were injected ip 4 hrs prior to or 2 hrs post -surgery. Rat IgG (Biolegend) was used as an antibody control and PBS as a vehicle control. As there was no difference between the 2, these groups were combined where indicated. IL-6, IL-10, IL-12p40, and IL-1beta were determined by commercially available immunoassays (R&D systems) and performed according to the manufacturers' specifications.
###end p 18
###begin title 19
Flow Cytometry
###end title 19
###begin p 20
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Flow cytometry was performed as previously described [18]. Whole blood or peritoneal lavage were collected and 1x106 cells were then labeled with the following antibodies: CD80, CD86, CD14 at optimal concentration for 45 min in the dark. Red blood cells were lysed with RBC lysis buffer then the cells were fixed with 0.1%paraformaldehyde and analyzed on a BD LSRII 8-color analyzer with FloJo software. All reagents were purchased from BDPharmigen. BD compensation beads were used to calibrate the instrument before each use. PMNs were identified by FSC/SSC characteristics; mononuclear cells by FSC/SSC, CD11b+ and CD14+, Isotype antibody labeled cells were used to control for nonspecific staining.
###end p 20
###begin title 21
Purification of PMN and preparation of Lipid rafts
###end title 21
###begin p 22
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human PMNs and lipids rafts were obtained from healthy volunteers and prepared as previously described [17]. Briefly, PMN were isolated from whole blood by Ficoll-Hypaque (Amersham Pharmacia) sedimentation. PMN (>99.9% granulocytes, >95% PMNs) were separated by dextran sedimentation (3% dextran in 0.9% NaCl solution @ 1 g, 30 min). PMN were activated by 100 ng/ml LPS (Sigma). For Detergent Resistant Membrane (DRM)/Lipid raft isolation, cells were lysed on ice with 200 microl of 1% Triton X-100 and gently mixed with an equal volume of 80% sucrose (wt/vol) and placed in the bottom of a Beckman centrifuge tube. The sample was then overlaid with 1000 microl of 30% sucrose and 600 microl of 5% sucrose spun for 16-24 h at 44,000 rpm at 4degreesC in a Beckman TLS 55 swing rotor using Beckman OPTIMA TLX Ultracentrifuge. 200 microl fractions were harvested serially from the top of the gradient. The DRM/raft fraction was obtained in fractions 1-4.
###end p 22
###begin title 23
Immunoprecipitation
###end title 23
###begin p 24
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocytes derived macrophages were isolated from healthy volunteers and prepared as previously described [17].Cells harvested and washed with PBS x3 and total cell lysate prepared using NP40 lysis buffer as previously described. Lysate (normalized for equal protein content) was then incubated with 10 microg antibodies to CD80 or CD86. One ml of extract was then incubated with end-over-end mixing for 2 hours at 4degreesC. Fifty microl of Protein A/G Sepharose (Santa Cruz Biotech) were washed with 1 ml of lysis buffer. This was repeated 3 times and then excess buffer was carefully removed. After the 2 hour incubation, the washed Protein A/G Sepharose was added to the immunoprecipitates and mixed for 1 hour at 4degreesC. The immunoprecipitates were washed 3X with 1 ml of lysis buffer. Samples then assayed by Western blot as previously described.
###end p 24
###begin title 25
Immunofluorescence Confocal Laser Microscopy
###end title 25
###begin p 26
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
Cells were attached to poly-L-Lysine-coated coverslips and fixed in 4% paraformaldehyde/PBS followed by acetone/methanol (1:1, vol./vol.). After blocking in non-specific IgG for 30 minutes, they were incubated with primary antibody (1:1000) over night. Following washing in PBS, cells were incubated with appropriate secondary antibodies containing Alexa-Fluor-labeled 488, 563, or 633 IgG (H+L) antibodies (Molecular Probes, OR) (1:500) for 30 minutes as previously described [17]. After final wash, samples were mounted with VectraShield mounting medium (Vector Laboratories) and images were obtained and quantified by Leica TCS NT imaging software. Images were processed with Photoshop (Adobe Systems, Mountain View, CA).
###end p 26
###begin title 27
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human studies
###end title 27
###begin p 28
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Bone1">[21]</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">Patients</span>
###xml 605 613 <span type="species:ncbi:9606">Patients</span>
All patients meeting SCCM/ACCP criteria for sepsis in the first 24 hrs of ICU stay were eligible for inclusion [21]. Patients were excluded for the following reasons; presence of a Do Not Resuscitate order or decision to institute comfort care measures, Hgb<7 g/dl or the presence of active bleeding requiring more than 2 units of packed red blood cells. After obtaining informed consent, 25 cc of blood was collected into glass (serum) or EDTA coated tubes (platelet poor plasma) within the first 24 hrs of admission. Clinical data including APACHE II scores were recorded at the time of the blood draw. Patients were followed for 28 days or until death or hospital discharge.
###end p 28
###begin title 29
Statistics
###end title 29
###begin p 30
Survival was analyzed by Kaplan-Meier analysis. All comparisons between groups were performed by Mann-Whitney t-test (2 groups) or ANOVA (multiple groups). Correlations were made with Spearman's test. All statistics were done with GraphPad Prism 5.0 (San Diego, CA).
###end p 30
###begin title 31
Results
###end title 31
###begin p 32
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 201 210 201 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g001">Figure 1A</xref>
###xml 324 333 324 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g001">Figure 1B</xref>
###xml 467 471 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
We first wished to establish that CD28 was serving as the predominant ligand for CD80 or CD86 engagement in sepsis. CD28-/- mice had improved overall and median survival compared to WT mice after CLP (Figure 1A). Improvement in survival was associated with attenuation in plasma IL-12 and IL-6, with little change in IL-10 (Figure 1B) or IL-1beta (not shown) 18 hrs after CLP. IFN-gamma, another cytokine regulated by CD28, was undetectable in both groups of animals [14]. We observed similar results in the lung (not shown), suggesting CD28 regulates inflammation in multiple tissue compartments. Together suggesting CD28, through either CD80 or CD86 is capable of mediating the inflammatory response and lethality of polymicrobial sepsis.
###end p 32
###begin title 33
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
CD28-/- mice are protected from lethality of polymicrobial sepsis.
###end title 33
###begin p 34
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 108 111 108 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Panel A-WT (n = 15) and CD28-/- (N = 15) underwent CLP and were monitored for survival. Panel B. WT and CD28-/- mice underwent CLP and were sacrificed at 18 hrs and plasma collected for cytokine analysis via commercially available ELISA. N = 5/group.
###end p 34
###begin p 35
###xml 166 169 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 498 507 498 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g002">Figure 2A</xref>
###xml 597 600 594 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 628 631 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 638 647 635 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g002">Figure 2B</xref>
###xml 687 696 684 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g002">Figure 2C</xref>
###xml 773 776 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 783 792 780 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g002">Figure 2D</xref>
###xml 1090 1094 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Newton1">[22]</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
We next sought to determine the relative contributions of CD80 and CD86 to mortality and inflammatory cytokine production in polymicrobial sepsis. Interestingly, CD80-/- mice had a marked improvement in median and overall survival compared to WT (p<0.001) and CD86-/- mice (p = 0.01). In contrast, there was only a modest benefit observed in median survival in CD86-/- mice compared to WT controls (median survival 42 vs. 25 hrs; p = 0.002) with no change in absolute survival (20% vs. 5%; p>0.2) (Figure 2A). This was associated with a preferential attenuation of plasma IL-6 and IL-1beta in CD80-/- mice compared to WT or CD86-/- mice (Figure 2B). We observed similar results in BALF (Figure 2C). However, in peritoneal lavage, IL-10 was preferentially attenuated in CD86-/- mice (Figure 2D). This being more consistent with some reports describing a preferential role for CD86 in regulating IL-10 production and is consistent with our previous description of differential CD86 expression in various tissue compartments in CLP, with increased levels of CD86 found in PL compared to blood [22].
###end p 35
###begin title 36
CD80 preferentially control lethality and inflammation in CLP.
###end title 36
###begin p 37
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 187 190 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 215 218 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 227 230 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
Panel A-WT (n = 20) and CD80-/- (N = 15) and CD86-/- (N = 15) underwent CLP and were monitored for survival. P<0.04 (CD80-/- vs. CD86-/-), p<0.001 (CD80-/- vs. WT) and p<0.01 (WT vs. CD86-/-). Panel B-D. WT and CD80-/- and CD86-/- mice underwent CLP and were sacrificed at 18 hrs and plasma (Panel B), BALF (Panel C) and PL (Panel D) were collected for cytokine analysis via commercially available ELISA. N = 8-10 mice/group. + = <0.1, * = <0.05.
###end p 37
###begin p 38
###xml 199 208 199 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g003">Figure 3A</xref>
###xml 567 576 567 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g003">Figure 3B</xref>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
We next used a pharmacologic approach to confirm the results with our knockout mice. Pre-treatment with anti-CD80 mAB significantly improved survival compared to either control IgG or anti-CD86 mAB (Figure 3A). Similar to observations with knockout mice, anti-CD86 modestly improved median survival compared to controls (42 vs. 18 hrs; p = 0.03), yet when combined with anti-CD80, antagonized the beneficial effects of anti-CD80. Anti-CD80 also proved to be an effective rescue therapy as post-CLP administration significantly improved survival compared to controls (Figure 3B). Similar to what we observed with pre-CLP therapy, addition of CD86 blockade antagonized the effects of anti-CD80 therapy.
###end p 38
###begin title 39
CD80 blockade preferentially improves survival after CLP.
###end title 39
###begin p 40
###xml 206 210 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
Panel A-WT C57BL/6 mice were administered either 250 microg anti-CD80, anti -CD86 or both 4 hrs prior to CLP and monitored for survival (n = 10/group). Data from anti -CD80/86 has been published previously [18]. P = 0.002 for anti-CD80 vs. control. Panel B-WT mice were administered control IgG or anti -CD80 or anti -CD80/86 (250 microg each) 2 hrs post-CLP and monitored for survival (n = 10/group). p = 0.002 for anti-CD80 vs. control.
###end p 40
###begin p 41
###xml 160 164 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 444 452 436 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 457 464 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 464 468 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 529 538 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4A</xref>
###xml 833 842 825 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4B</xref>
###xml 956 965 948 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4B</xref>
###xml 1038 1047 1030 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4B</xref>
###xml 1149 1158 1141 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4B</xref>
###xml 1414 1423 1406 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g004">Figure 4C</xref>
We next sought to determine a potential mechanism for CD80 regulation of inflammation. Prior studies suggest CD28 induces NF-kappaB induction via CD80 and CD86 [14]. At baseline, Interleukin-1 receptor associated kinase-M (IRAK-M), a negative regulator of NF-kappaB signaling, was associated with CD80 as opposed to CD86. Upon addition of neutrophil lipid rafts, previously reported by our lab as a source of CD28 and stimulator of macrophages in vitro and in vivo[17], the association of CD80 with IRAK-M at 1 hr was abolished (Figure 4A). In contrast, there was an increase in association of CD86 and IRAK-M 1 hr after the addition of lipid rafts. The interaction between CD80 and IRAK-M was confirmed by immunofluorescent microscopy, which demonstrated that at baseline, there was significant co-localization of CD80 and IRAK-M. (Figure 4B, Row 1) After addition of PMN lipid rafts, while there was no change in the amount of CD80 and IRAK-M, by 4 hrs (Figure 4B Row 3), the vast majority of CD80 was no longer associated with IRAK-M (Figure 4B Row 3). In contrast, the amount of IRAK-M associated with CD86 actually increased after stimulation (Figure 4B Row 5). Finally, we confirmed that IRAK-M did indeed associate with TRAF-6 in our system and that there was a slight decrease in this association with PMN lipid raft stimulation providing another mechanism for de-repression of macrophages by PMN contact (Figure 4C).
###end p 41
###begin title 42
PMN membranes disassociate IRAK-M from CD80.
###end title 42
###begin p 43
Macrophages were treated with PMN lipid rafts for various times Panel A. Co-IP demonstrates CD80 binds IRAK-M in resting PMA differentiated THP-1 macrophages, lane 1. One hour after lipid raft treatment IRAK-M disassociates from CD80, lane 2. CD86 binds little IRAK-M in resting macrophages, lane3. There is association of IRAK-M with CD86 one hour after lipid raft addition, lane4. Panel B. Confocal microscopy of resting monocyte derived macrophages at baseline (Row 1,4) or stimulated with PMN lipid rafts for 1 hr (Row 2,5) or 4 hrs (Row 3,6). IRAK-M (Red), CD80 (Left Panel-green) or CD86 (Right Panel-green) and co-localization (Yellow). Nucelar stain with DAPI (blue). Panel C. PMA differentiated THP-1 macrophages were stimulated with PMN lipids rafts and harvested at the designated time point. Whole cell extracts were IP for TRAF-6 and blotted for IRAK-M. All lanes (panel A and C) were normalized for protein prior to immunoprecipitation.
###end p 43
###begin p 44
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 284 291 284 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006600-t001">Table 1</xref>
###xml 421 430 421 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g005">Figure 5A</xref>
###xml 510 519 510 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g005">Figure 5B</xref>
###xml 780 795 780 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g005">Figure 5C and E</xref>
###xml 856 865 856 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g005">Figure 5D</xref>
###xml 956 971 956 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006600-g005">Figure 5F and G</xref>
###xml 1029 1036 1029 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 133 139 <span type="species:ncbi:9606">humans</span>
###xml 350 356 <span type="species:ncbi:9606">humans</span>
Finally, we sought to expand our previously reported data and determine whether differential expression of CD80 and CD86 occurred in humans with sepsis and if expression levels could serve as biomarkers for outcome [18]. Clinical characteristics of enrolled subjects are presented in Table 1. CD80, was upregulated on circulating monocytes in septic humans, with higher levels associated with both the presence of shock (Figure 5A) and correlating with overall severity of illness as determined by SOFA score (Figure 5B). There was no association between levels of CD80 and survival or cytokine levels. A relatively protective role for CD86 was supported by the presence of higher levels of expression on circulating monocytes in survivors and those with negative blood cultures (Figure 5C and E). Higher levels of CD86 also correlated with ICU free days (Figure 5D). Finally, levels of CD86 correlated inversely with circulating levels of IL-10 and IL-6 (Figure 5F and G) suggesting a relatively anti-inflammatory role for CD86 in vivo.
###end p 44
###begin title 45
###xml 44 49 <span type="species:ncbi:9606">human</span>
Differential Regulation of CD80 and CD86 in human sepsis.
###end title 45
###begin p 46
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 524 525 524 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with sepsis (n = 31) had blood drawn within 24 hrs of ICU admission. Samples analyzed by flow cytometry and plasma underwent cytokine analysis. Panel A-CD14+ monocytes expression of CD80 in subjects with (n = 20) or without (N = 10) septic shock. Panel B- Correlation between CD14+ monocytes expression of CD80 and SOFA Score. Panel C- CD14+ monocytes expression of CD86 in survivors (N = 24) and non-survivors (N = 6). Panel D- Correlation between CD14+ monocytes expression of CD86 and ICU Free days. Panel E-CD14+ monocytes expression of CD86 in subjects with (n = 16) or without (N = 14) bacteremia on presentation. Panels F and G- Correlation between CD14+ monocytes expression of CD86 and IL-6 (Panel F) and IL-10 (Panel G).
###end p 46
###begin title 47
Clinical Characteristics of enrolled subjects. Absolute values are presented are Mean+/-SEM.
###end title 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 399 403 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 405 409 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 411 415 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Venuprasad1">[23]</xref>
###xml 619 622 615 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Saha1">[6]</xref>
###xml 624 628 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Tzianabos1">[24]</xref>
###xml 768 772 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Suntharalingam1">[25]</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
###xml 761 767 <span type="species:ncbi:9606">humans</span>
One of the major findings of this paper is the observation of improved survival in CD28-/- mice after CLP. The ability of CD28 to regulate inflammation in the innate immune response to sepsis is consistent with prior reports documenting CD28 expression on PMNs and the ability of CD28, either soluble or in PMN lipid rafts, to induce NF-kappaB and pro-inflammatory cytokine production via CD80/CD86 [14], [17], [23]. Our results are also consistent with earlier reports suggesting an important role for CD28 in regulating abdominal abscess formation in CLP as well as the role for CD28 in mediating toxic shock in mice [6], [24]. Finally, these data support the recent observations of lethal cytokine storm in with administration of an agonist CD28 antibody in humans [25]. Together these data imply a prominent role for the CD28-CD80/86 system in regulating multiple pro-inflammatory cytokines in the innate immune response.
###end p 49
###begin p 50
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 218 221 218 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 234 237 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 428 431 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 440 443 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 574 578 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Orabona1">[14]</xref>
###xml 724 728 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hoshino1">[17]</xref>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Okano1">[19]</xref>
###xml 736 740 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hosiawa1">[20]</xref>
###xml 924 925 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
###xml 1313 1317 <span type="species:ncbi:10090">mice</span>
While CD28 is capable of activating both CD80 and CD86, the relative contribution of the interaction and differential effect of these in vivo has been less well defined. The finding of improved overall survival in CD80-/- and not CD86-/- mice implies CD80 is the dominant receptor for regulating lethality in the innate immune response in the early stages of CLP. This is corroborated by the relative attenuation in IL-6 in CD80-/- vs. CD86-/- mice and is consistent with the known ability of CD28 to regulate IL-6 production from dendritic cells in a CD80 dependent manner [14]. Interestingly, recent studies suggest CD86, not CD80, plays a dominant role in mediating graft vs. host disease and abdominal abscess formation [17], [19], [20]. The reasons for these contrasting results are likely due to the source of CD28 and the chronicity of inflammation. In those model systems, there is a much more prominent role for CD4+ T-cells, as opposed to PMNs or soluble CD28 as observed in the early phases of sepsis. Future studies are required to determine the interaction between the cellular source of CD28 and predilection for CD80 vs. CD86 activity. Finally, the improved survival with anti-CD80 as opposed to anti-CD86 confirms the results obtained with the knockout mice and the ability of anti-CD80 to rescue mice when given after the onset of sepsis suggests this is a potential therapeutic target as well.
###end p 50
###begin p 51
###xml 460 464 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Kobayashi1">[26]</xref>
The ability of CD80 to regulate inflammation can be in part explained by its known ability to regulate the induction of NF-kappaB in response to CD28 engagement. The NF-kappaB signaling complex contains numerous adapter molecules which serve to both stimulate and repress NF-kappaB signaling. IRAK-M is a well described repressor of NF-kappaB signaling and successful induction of pro-inflammatory signals requires loss of IRAK-M from the NF-kappaB signalsome [26]. We now show that IRAK-M is directly associated with CD80 and CD86 and that stimulation of macrophages with PMN lipid rafts causes preferential loss of this association with CD80, providing one potential mechanism to explain the preferential ability of CD80 to regulate multiple inflammatory cytokines. Further studies are required to ascertain whether this is specific for the presence and source of CD28 (PMNs vs. T-cells), explaining the predilection for CD80 in innate immunity while CD86 appears more prominent in the adaptive immune response.
###end p 51
###begin p 52
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 998 1005 998 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 359 365 <span type="species:ncbi:9606">humans</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 384 390 <span type="species:ncbi:9606">humans</span>
Another potential reason for the prominent effect for CD80 in innate immunity, centers on the differential expression of CD80 and CD86 in sepsis. Our group and others have previously demonstrated that sepsis is associated with marked an increase in CD80 expression and a loss of constitutively expressed CD86 in mice [18]. We now extend these observations to humans. Similar to mice, humans with sepsis exhibit a loss of CD86 and upregulation of CD80 on circulating monocytes. A prominent role for CD80 in regulating lethal inflammation is supported by a direct correlation between CD80 levels and severity of illness (SOFA score) and presence of shock. Of even greater interest was the inverse correlation of CD86 and severity of illness, with loss of CD86 being associated with mortality, a reduction in ICU free days and increased likelihood of shock. Further, the negative association of CD86 with circulating levels of IL-10 and IL-6 suggest a potential direct anti-inflammatory role for CD86 in vivo. However, the mechanism of CD86 loss remains incompletely understood.
###end p 52
###begin p 53
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Wong1">[27]</xref>
###xml 714 722 714 722 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">isolated</underline>
###xml 1052 1056 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Sharpe1">[15]</xref>
###xml 1058 1062 1058 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-vanderMerwe1">[28]</xref>
###xml 1064 1068 1064 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Sansom1">[29]</xref>
###xml 1070 1074 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Linsley1">[30]</xref>
###xml 1386 1390 1386 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Grohmann1">[16]</xref>
###xml 1546 1550 1546 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Mandelbrot1">[31]</xref>
###xml 1858 1862 1858 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Nolan1">[18]</xref>
###xml 448 453 <span type="species:ncbi:9606">human</span>
While our data provide strong evidence for a predominant role for CD80 in regulation of lethal inflammation in sepsis, the role for CD86 remains conflicted. Overall, CD86 appears to exert a protective role, especially in the context of CD80 inhibition. This is supported by the antagonistic effects of CD86 blockade/deletion on survival in the setting of CD80 blockade. A potentially beneficial/protective role for CD86 is further supported by our human observations that persistence of CD86 expression is associated with improved outcome. This finding is consistent with a prior study showing reduced levels of CD86 mRNA in lethal pediatric septic shock [27]. However, the modest survival benefit associated with isolated CD86 blockade/deletion suggests that some of these protective effects may be modulated by CD80 as well. The reason for the predilection of CD80 for lethality and CD86 for protection may lie in their relative affinities and binding kinetics for their ligands, CD28 and CTLA4, with CD80 having a relative higher affinity for CTLA4 [15], [28], [29], [30]. Thus we cannot discount a potentially protective role for a CTLA4-CD86 interaction which is unmasked by the absence of CD80 in our system. This is a distinct possibility given the ability of CTLA4 to both inhibit CD28 engagement as well as direct induce signaling, including induction of tryptophan catabolism [16]. Investigators have also described a CD28/CTLA4 independent ligand for CD86, which may also modulate our system both signaling via the receptor and ligand [31]. Addressing both of these possibilities will be the subject of further studies. Finally, it is highly probable, that the role of CD86 may indeed be tissue compartment specific. In our previous study, we noticed differential regulation of CD86 in blood (down regulation) and peritoneal lavage (upregulation) [18]. This most likely explains the differential cytokine response, especially IL-10, between these differing compartments. However, we are still unable to provide a mechanism for this differential compartment specific regulation.
###end p 53
###begin p 54
###xml 362 365 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Hotchkiss1">[2]</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006600-Schwulst1">[32]</xref>
###xml 139 145 <span type="species:ncbi:10090">murine</span>
However, there are many important limitations to our study. Most notably is the use of a highly lethal form of polymicrobial sepsis in our murine model. It is well established that there are multiple phases to the immune response in sepsis, with the early phases dominated by massive pro-inflammatory cytokine production, and the latter phase by immunoparalysis [2], [32]. It is likely, that during the transition to these latter stages, a more prominent role for CD86 could be observed. In addition, the mechanism for loss of CD86 expression also remains incompletely understood. Whether this results in a true loss of expression or recruitment of additional low expressing CD86 monocytes from the bone marrow is also unclear. Future studies will be required to address these questions. Finally, while our data now suggest IRAK-M may be capable of differentially regulating CD80 and CD86 mediated cellular activation, there are still multiple limitations to this data. Most notably, is we can not explain the reason for the differential affinity for CD80 and CD86 for IRAK-M under resting or stimulated conditions. Understanding the reasons for this and the true biological significance of this association will be the subject of future studies detailing all members of the NF-kappaB signaling complex.
###end p 54
###begin p 55
In conclusion, we document a pivotal role for CD28-CD80 interaction in regulating the lethality of the acute phases of sepsis and septic shock. This occurs predominantly through the interaction between CD80 and CD28. These data suggest that any future therapies targeting this system in sepsis be directed specifically at CD80.
###end p 55
###begin title 56
References
###end title 56
###begin article-title 57
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
###end article-title 57
###begin article-title 58
The pathophysiology and treatment of sepsis.
###end article-title 58
###begin article-title 59
The epidemiology of sepsis in the United States from 1979 through 2000.
###end article-title 59
###begin article-title 60
###xml 67 72 <span type="species:ncbi:9606">human</span>
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
###end article-title 60
###begin article-title 61
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
###end article-title 61
###begin article-title 62
Protection against lethal toxic shock by targeted disruption of the CD28 gene.
###end article-title 62
###begin article-title 63
Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture.
###end article-title 63
###begin article-title 64
Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality.
###end article-title 64
###begin article-title 65
Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture.
###end article-title 65
###begin article-title 66
CD40 contributes to lethality in acute sepsis: in vivo role for CD40 in innate immunity.
###end article-title 66
###begin article-title 67
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies.
###end article-title 67
###begin article-title 68
###xml 15 19 <span type="species:ncbi:10090">mice</span>
OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection.
###end article-title 68
###begin article-title 69
###xml 70 76 <span type="species:ncbi:10090">murine</span>
###xml 90 97 <span type="species:ncbi:1392">anthrax</span>
Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax.
###end article-title 69
###begin article-title 70
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86.
###end article-title 70
###begin article-title 71
The B7-CD28 superfamily.
###end article-title 71
###begin article-title 72
CTLA-4-Ig regulates tryptophan catabolism in vivo.
###end article-title 72
###begin article-title 73
###xml 65 70 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis.
###end article-title 73
###begin article-title 74
CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis.
###end article-title 74
###begin article-title 75
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Differential role of CD80 and CD86 molecules in the induction and the effector phases of allergic rhinitis in mice.
###end article-title 75
###begin article-title 76
CD80/CD86 costimulation regulates acute vascular rejection.
###end article-title 76
###begin article-title 77
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.
###end article-title 77
###begin article-title 78
Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response.
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neutrophil-expressed CD28 interacts with macrophage B7 to induce phosphatidylinositol 3-kinase-dependent IFN-gamma secretion and restriction of Leishmania growth.
###end article-title 79
###begin article-title 80
Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathway.
###end article-title 80
###begin article-title 81
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
###end article-title 81
###begin article-title 82
IRAK-M is a negative regulator of Toll-like receptor signaling.
###end article-title 82
###begin article-title 83
Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome.
###end article-title 83
###begin article-title 84
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
###end article-title 84
###begin article-title 85
What's the difference between CD80 and CD86?
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
###end article-title 86
###begin article-title 87
###xml 37 41 <span type="species:ncbi:10090">mice</span>
B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
###end article-title 87
###begin article-title 88
Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis.
###end article-title 88
###begin p 89
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 89
###begin p 90
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Funding Sources: NIH M01 00096, T32ES007267, K23HL084191, K24A1080298, R01HL057879, R01A1067522, Stony-Wold Herbert Fund, ECRIP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 90

